Home›Stock Screener›Acutaas Chemicals

Acutaas Chemicals Share Price Today | Stock Price & Acutaas Chemicals Share Screener

ACUTAAS Pharmaceuticals & Biotechnology
Live Share Price NSE
₹3991.30
▲ 48.40 (1.23%)
2026-11-18 00:00:00
Live Share Price BSE
₹3995.60
▲ 51.75 (1.31%)
2026-11-18 00:00:00

As of November 18, 2026, the live Acutaas Chemicals share price (NSE: ACUTAAS) is ₹3,991.30 on NSE and ₹3,995.60 on BSE, up 1.23% from the previous close, with shares trading between ₹3,934.20 and ₹4,017.60 in today's trading session, and a 52-week range of ₹1,602.50–₹4,039.10. Track ACUTAAS market capitalization to gauge the company's total market size. Use the Acutaas Chemicals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Acutaas Chemicals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹442 and net income of ₹123, with EBITDA of ₹181, an operating margin of 40.0% and a profit margin of 27.8%.

Acutaas Chemicals Market Cap ₹32,280.96 Cr.
ACUTAAS P/E Ratio (TTM) 73.60
Acutaas Chemicals P/B Ratio 17.38
EPS (TTM) ₹43.51
Dividend Yield 0.06%
Debt to Equity 0.02
ACUTAAS 52 Week High ₹4039.10
Acutaas Chemicals 52 Week Low ₹1602.50
Operating Margin 40.00%
Profit Margin 27.83%
ACUTAAS Revenue (TTM) ₹442.00
EBITDA ₹181.00
Net Income ₹123.00
Total Assets ₹1,984.00
Total Equity ₹1,711.00

Acutaas Chemicals Share Price Chart

Track the current stock price of Acutaas Chemicals with an interactive chart. Analyse ACUTAAS share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Acutaas Chemicals stock quote in one place.

The quote of ₹3,991.30 sits between the 52-week low of ₹1,602.50 and the 52-week high of ₹4,039.10, and the latest session moved 1.23% from the previous close.

Acutaas Chemicals Company Profile - Fundamental Screener

Screen Acutaas Chemicals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ACUTAAS shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE00FF01025.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE00FF01025

Acutaas Chemicals Balance Sheet Screener

Screen ACUTAAS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹1,984, up from ₹1,549 in 2025.

Latest statistics put total assets at ₹1,984 and shareholder funds at ₹1,711, with a leverage ratio of 0.02.

Item 2026 2025 2024 2023 2022 2021 2020 2019

Assets

Total Assets 1,984 1,549 1,096 767 659 413 232 213
Current Assets 0 0 0 0 0 0 0 0
Fixed Assets 745 570 427 259 205 186 85 79

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0
Current Liabilities 42 27 128 10 7 80 26 25
Non-Current Liabilities 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 1,711 1,320 683 594 522 167 112 82
Share Capital 41 41 37 36 36 32 11 11
Reserves & Surplus 1,613 1,269 637 558 486 135 101 72

Acutaas Chemicals Income Statement Screener - Profit & Revenue Analysis

Screen Acutaas Chemicals income statement and profit fundamentals. Analyze ACUTAAS quarterly results. Acutaas Chemicals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Sept, revenue was ₹442 and net profit was ₹123, equal to earnings per unit of ₹15.29, at an operating margin of 40%.

In that period expenses were ₹261, interest cost ₹1 and tax ₹44. The next period listed, 2026-Jun, shows revenue of ₹332 and net profit of ₹75.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun 2023-Mar

Revenue and Expenses

Revenue 442 332 444 398 316 223 314 277 255 178 226 170 174 155 186
Expenses 261 217 249 243 211 156 224 206 198 147 182 140 179 120 146

Operating Costs and Margins

EBITDA 181 115 195 155 105 67 91 70 57 31 44 30 -5 35 41
Operating Profit % 40.00% 34.00% 42.00% 38.00% 31.00% 25.00% 28.00% 25.00% 20.00% 17.00% 19.00% 16.00% -4.00% 22.00% 22.00%
Depreciation 13 10 10 10 8 8 7 6 7 6 5 4 4 4 3
Interest 1 1 1 1 1 1 1 1 1 4 2 3 1 1 1

Profit and Earnings

Profit Before Tax 167 104 184 145 96 58 83 63 50 20 37 24 -10 31 37
Tax 44 29 50 38 24 14 20 18 13 5 12 6 7 9 10
Net Profit 123 75 134 106 72 44 63 46 38 15 26 18 -17 22 27
EPS 15.29 9.07 16.09 13.19 8.82 5.41 7.80 11.35 9.38 3.67 6.85 4.83 -4.67 4.57 7.47

Acutaas Chemicals Cash Flow Screener - Liquidity Fundamentals

Screen ACUTAAS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹292, and net cash flow was an inflow of ₹30.

Over the same period, investing activities used ₹266 and financing activities provided ₹4.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 292 118 125 66 -12 28 27 15 9 29
Investing Activities -266 -224 -365 -33 -121 -101 -24 -21 -25 -19

Financing and Net Cash

Financing Activities 4 261 239 -12 140 72 0 6 15 -7
Net Cash Flow 30 156 -1 20 8 -1 3 0 -2 3

Acutaas Chemicals Shareholding Pattern Screener

See Acutaas Chemicals shareholding pattern with promoter, FII, and DII holdings. Check Acutaas Chemicals promoter holding and ownership changes for ACUTAAS on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Sept, promoters held 32.66%, foreign institutions 22.62%, domestic institutions 19.40% and the public 21.15%, spread across 147,026 shareholders.

The shareholder count was 147,026 in 2026-Sept, compared with 125,569 in 2026-Jun.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec

Promoter Holding

Promoter Holding 32.66% 32.66% 32.66% 32.66% 32.66% 32.66% 35.96% 35.96%

Institutional Investors

FII Holding 22.62% 21.61% 19.48% 16.67% 16.85% 16.94% 16.48% 15.52%
DII Holding 19.40% 19.56% 19.60% 21.70% 22.59% 22.38% 18.31% 20.24%

Government, Public and Others

Govt Holding 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
Public Holding 21.15% 21.72% 23.21% 23.53% 22.79% 23.27% 24.19% 23.56%
Other Holding 4.16% 4.44% 5.03% 5.43% 5.10% 4.74% 5.05% 4.71%
Shareholder Count 147,026 125,569 112,939 110,363 108,664 119,890 114,060 95,756

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Acutaas Chemicals. Acutaas Chemicals dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹2.50 per unit for 2026-March, a yield of 0.06%, compared with ₹1.50 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹2.50, ₹1.50 and ₹3.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹2.50 0.06%
2025-March ₹1.50 0.06%
2024-March ₹3.00 0.25%
2023-March ₹3.00 0.55%
2022-March ₹3.00 0.67%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Acutaas Chemicals Stock Index Membership - Nifty & Sensex

See which indices include Acutaas Chemicals stock. Check ACUTAAS index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 5 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP, NIFTY MICROCAP250.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
NIFTY MICROCAP250
NIFTY TOTAL MKT

Acutaas Chemicals Market Events Screener - Corporate Actions

Get Acutaas Chemicals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Acutaas Chemicals stock events that may affect ACUTAAS share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 27, 2026, with a record date of October 27, 2026.

It is followed by Annual General Meeting dated September 24, 2026 and Dividend dated September 17, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-10-27 2026-10-27 Quarterly Result Announcement NA 6.20%
2026-09-24 2026-09-24 Annual General Meeting NA 3.04%
2026-09-17 2026-09-17 Dividend ₹ 2.50 /share 33.69%
2026-07-24 2026-07-24 Quarterly Result Announcement NA -4.40%
2026-04-30 2026-04-30 Quarterly Result Announcement NA 4.41%
2026-01-28 2026-01-28 Quarterly Result Announcement NA 6.40%
2025-10-17 2025-10-17 Quarterly Result Announcement NA 9.21%
2025-09-25 2025-09-25 Annual General Meeting NA 2.54%
2025-09-18 2025-09-18 Dividend ₹ 1.50 /share 30.23%
2025-07-30 2025-07-30 Quarterly Result Announcement NA -1.68%
2025-05-10 2025-05-10 Extraordinary General Meeting NA -1.28%
2025-05-02 2025-05-02 Quarterly Result Announcement NA 2.71%
2025-04-25 2025-04-25 Split 5:10 -1.69%
2025-04-16 2025-04-16 Change Of Name NA 0.00%
2025-01-28 2025-01-28 Quarterly Result Announcement NA -3.43%

Acutaas Chemicals Competitors Screener - Peer Stocks Comparison

Screen ACUTAAS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 448,676 40.80 61,674 12.69% 11,565 60.46
Divis Laboratories 295,997 87.70 11,067 13.95% 2,568 68.76
Torrent Pharmaceuticals 177,586 85.00 13,886 20.34% 2,138 47.23
Laurus Labs 126,325 89.90 6,868 22.01% 890 57.04
Zydus Life Science 120,119 27.60 27,658 17.64% 5,026 55.91
Dr Reddys Laboratories 115,854 41.80 35,059 3.90% 4,158 71.26
Cipla 112,131 39.50 29,045 2.24% 3,870 53.06
Mankind Pharma 107,805 47.90 14,636 14.85% 1,938 61.37
Aurobindo Pharma 103,229 25.80 34,145 5.56% 3,503 60.39
Lupin 89,172 17.30 29,039 26.75% 5,356 39.39

Acutaas Chemicals Company Announcements - News & Reports Screener

Screen ACUTAAS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 10, 2026.

The next most recent announcements are dated November 10, 2026 and November 2, 2026.

Date Update Actions
2026-11-10 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-11-10 Annual Sustainability Report For The Financial Year 2025-26 -
2026-11-02 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-11-02 Announcement under Regulation 30 (LODR)-Change in Management -
2026-10-28 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-10-27 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-10-27 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-10-27 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-10-27 Unaudited Standalone And Consolidated Financial Results For Second Quarter And Half Year Ended September 30 2026 -
2026-10-27 Board Meeting Outcome for Outcome Of Board Meeting Held On October 27 2026 -
2026-10-22 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-22 Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended September 30 2026 Scheduled On October 27 2026. -
2026-10-17 Announcement under Regulation 30 (LODR)-Updates on Acquisition -
2026-10-06 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-09-26 Announcement under Regulation 30 (LODR)-Change in Management -
2026-09-26 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-24 Announcement under Regulation 30 (LODR)-Acquisition -
2026-09-24 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-22 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-09-22 Closure of Trading Window -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹3,991.30, within a 52-week range of ₹1,602.50 to ₹4,039.10. The P/E ratio is 73.60 and the P/B ratio is 17.38, with earnings per unit of ₹43.51. Market capitalisation stands at ₹32,280.96 Cr and the dividend yield is 0.06%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 8 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.